Compare Crispr Therapeutics AG (CRSP) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Crispr Therapeutics AG trades at $51.49 (market cap $4.97B), while Direxion Daily Semiconductor Bull 3X Shares trades at $164.39. The key difference: Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SOXL | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $76.78 | $300.77 |
52-Week Low | $44.34 | $23.99 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SOXL, a 3x leveraged semiconductor ETF, trades at $165.37, down 13.99% in 24 hours amid sector-wide volatility. Technical indicators show a bearish trend with support at $159 and resistance at $168. Recent news highlights sharp declines driven by SK Hynix's expansion and AI stock sell-offs, exposing the fund's sensitivity to leverage decay and chip sector swings.
The outlook remains high-risk due to leveraged structure and semiconductor cyclicality. Near-term pressure from oversupply concerns and hedge fund selling suggests caution, though dips may attract speculative buys. Key risks include volatility decay and broader tech sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
